Nathan Hardy - Mar 7, 2024 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Role
EVP, Chief Financial Officer
Signature
/s/ Julie Shah, Attorney-in-Fact for Nathan Hardy
Stock symbol
SANA
Transactions as of
Mar 7, 2024
Transactions value $
$0
Form type
4
Date filed
3/8/2024, 04:16 PM
Previous filing
Nov 3, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SANA Restricted Stock Units Award $0 +67.1K $0.00 67.1K Mar 7, 2024 Common Stock 67.1K Direct F1, F2
transaction SANA Stock Option (Right to Buy) Award $0 +302K $0.00 302K Mar 7, 2024 Common Stock 302K $9.58 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.
F2 The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
F3 The option vests and becomes exercisable as to 25% of the underlying shares on March 7, 2025 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.